The current investigation focused on exploring the underlying mechanism of aberrant glycosylation of SEMA7A in HNSCC and its role in tumor progression, EGFR-targeted therapy, immunotherapy, and splicing regulation. The gene discussed is EGFR; the disease is neoplasm.